A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

N. Newsome, Philip; Buchholtz, Kristine; Cusi, Kenneth; Linder, Martin; Okanoue, Takeshi; Ratziu, Vlad; J. Sanyal, Arun; Sejling, Anne‐Sophie; A. Harrison, Stephen

doi:10.1056/nejmoa2028395

Public

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Published in New England Journal of Medicine • Nov 13, 2020

Authors:

Philip N. Newsome

Kristine Buchholtz

Kenneth Cusi

Abstract

BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known. METHODS: We conduc...

Subject

Semaglutide

Nonalcoholic steatohepatitis

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!